OKYO Pharma CMO buys 20,000 company shares

OKYO Pharma reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on Nasdaq at $1.40 per share.

Accepted by SEC EDGAR 07/22/2026 - 07:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on Nasdaq at $1.40 per share.

The company is a clinical-stage biopharmaceutical developer of therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases and plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.

Key Figures

CMO share purchase: 20,000 shares Purchase price: $1.40 per share Planned trial enrollment: approximately 111 patients +1 more

4 metrics

CMO share purchase 20,000 shares Ordinary shares bought on Nasdaq by Chief Medical Officer

Purchase price $1.40 per share Price paid for ordinary shares on Nasdaq

Planned trial enrollment approximately 111 patients Planned global Phase 3 pivotal clinical trial in NCP

Trial phase Phase 3 Planned pivotal clinical trial of urcosimod for neuropathic corneal pain

Key Terms

neuropathic corneal pain (NCP), anterior segment eye diseases, Phase 3 pivotal clinical trial, single-dose regimen, +1 more

5 terms

neuropathic corneal pain (NCP) medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"developing innovative therapies for the treatment of NCP and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

Phase 3 pivotal clinical trial medical

"plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"to evaluate a single-dose regimen of urcosimod for the treatment of NCP"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

urcosimod medical

"evaluate a single-dose regimen of urcosimod for the treatment of NCP"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did OKYO (OKYO) disclose in this report?

OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, bought 20,000 ordinary shares on Nasdaq at $1.40 per share. The transaction involves company ordinary shares traded on the Nasdaq Capital Market and is highlighted in the company’s July 22, 2026 news announcement.

Who at OKYO (OKYO) purchased shares and in what role do they serve?

Flavio Mantelli, MD, PhD, OKYO Pharma’s Chief Medical Officer, purchased the shares. His role includes overseeing the company’s clinical development programs, including investigational therapies for neuropathic corneal pain and anterior segment eye diseases.

How many OKYO (OKYO) shares were bought and at what price?

A total of 20,000 OKYO Pharma ordinary shares were purchased at $1.40 per share on Nasdaq. This insider transaction reflects a direct market purchase of the company’s Nasdaq-listed ordinary shares by its Chief Medical Officer.

What clinical trial is OKYO (OKYO) planning for neuropathic corneal pain?

OKYO plans a global Phase 3 pivotal trial for urcosimod in neuropathic corneal pain (NCP). The study is expected in the second half of this year and will enroll approximately 111 patients to evaluate a single-dose regimen.

What therapeutic areas is OKYO (OKYO) focused on?

OKYO Pharma is developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. It is a clinical-stage biopharmaceutical company with ordinary shares listed on the Nasdaq Capital Market under the symbol OKYO.

On which exchange are OKYO (OKYO) ordinary shares listed?

OKYO Pharma’s ordinary shares are listed for trading on the Nasdaq Capital Market. The company’s ticker symbol is OKYO, and the disclosed insider purchase was executed on the Nasdaq market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 22, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: July 22, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 22, 2026

4

Exhibit 99.1

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

London and New York, NY, July 22, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 6.0 KB
• EX-99 GRAPHIC 4.4 KB